Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Natnael Yeneneh Belie, Fisseha Admassu Ayele, Belayneh Mengist, Abiy Maru Alemayehu, Abel Sinshaw Assem, Sofonias Addis Fekadu & Betelhem Temesgen Yibekal. (2023) Patients’ Satisfaction with Topical Anti-Glaucoma Medications and Associated Factors at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021. Clinical Optometry 15, pages 139-146.
Read now
Read now
Jason Bacharach, Iqbal Ike K Ahmed, Elizabeth D Sharpe, Michael S Korenfeld, Steven Zhang & Christophe Baudouin. (2023) Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clinical Ophthalmology 17, pages 2575-2588.
Read now
Read now
Carl Erb, Ingeborg Stalmans, Milko Iliev & Francisco José Muñoz-Negrete. (2021) Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost. Clinical Ophthalmology 15, pages 931-938.
Read now
Read now
Jack Phu, Ashish Agar, Henrietta Wang, Katherine Masselos & Michael Kalloniatis. (2021) Management of open‐angle glaucoma by primary eye‐care practitioners: toward a personalised medicine approach. Clinical and Experimental Optometry 104:3, pages 367-384.
Read now
Read now
Jose M Martinez-de-la-Casa, Shaantanu Donde & Joanna Wierzbowska. (2019) Latanoprost, a balanced prostaglandin. Expert Review of Ophthalmology 14:1, pages 61-72.
Read now
Read now
Mario A Economou, Helene Kolstad Laukeland, Iwona Grabska-Liberek & Jean-François Rouland. (2018) Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. Clinical Ophthalmology 12, pages 2399-2407.
Read now
Read now
Daniel Edward Robert Beck, Karim El-Assal, Ken McGarry & Nicholas Kloster Wride. (2017) Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clinical Ophthalmology 11, pages 1565-1566.
Read now
Read now
Valencia Hui Xian Foo, Sarah En Mei Tan, David Ziyou Chen, Shamira A Perera, Charumathi Sabayanagam, Eva Katie Fenwick, Tina T Wong & Ecosse L Lamoureux. (2017) Areas and factors associated with patients’ dissatisfaction with glaucoma care. Clinical Ophthalmology 11, pages 1849-1857.
Read now
Read now
Articles from other publishers (13)
Barbara Cvenkel & Miriam Kolko. (2022) Devices and Treatments to Address Low Adherence in Glaucoma Patients: A Narrative Review. Journal of Clinical Medicine 12:1, pages 151.
Crossref
Crossref
Bridgitte Shen Lee, Ranjan Malhotra, Kenneth Sall, Brittany Mitchell & James Peace. (2022) Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension. Clinical Ophthalmology Volume 16, pages 2285-2293.
Crossref
Crossref
T. N. Malishevskaya, S. Yu. Petrov, S. M. Kosakyan & S. A. Vlasova. (2021) When is preservative-free therapy of glaucoma needed and advisable?. Russian Ophthalmological Journal 14:3, pages 25-31.
Crossref
Crossref
Javier F. Casiraghi, Daniel Grigera, J. Alejo Peyret, Melina del Papa & María Silvia Passerini. (2021) Efficacy and Tolerability of a New Latanoprost 0.005% BAK-Free Nanoemulsion: A Nonrandomized Open-Label Trial. Re:GEN Open 1:1, pages 110-116.
Crossref
Crossref
Paul Harasymowycz, Cindy Hutnik, Jean-François Rouland, Francisco J. Muñoz Negrete, Mario A. Economou, Philippe Denis & Christophe Baudouin. (2021) Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis. Advances in Therapy 38:6, pages 3019-3031.
Crossref
Crossref
Philippe Denis, Susana Duch, Enping Chen, Per Klyve, Jesper Skov, Païvi Puska & Carl Erb. (2020) European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment. European Journal of Ophthalmology 31:3, pages 1056-1063.
Crossref
Crossref
Chloé Chamard, Sophie Larrieu, Christophe Baudouin, Alain Bron, Max Villain & Vincent Daien. (2020) Preservative‐free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008‐2016. Acta Ophthalmologica 98:7.
Crossref
Crossref
Eva K Fenwick, Ryan EK Man, Tin Aung, Pradeep Ramulu & Ecosse L Lamoureux. (2020) Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucoma. Progress in Retinal and Eye Research 76, pages 100801.
Crossref
Crossref
Marisa Meloni, Silvia Balzaretti & Laura Ceriotti. (2019) Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops. Regulatory Toxicology and Pharmacology 106, pages 81-89.
Crossref
Crossref
V. V. Neroev, A. V. Zolotarev, E. V. Karlova, O. A. Kiseleva, M. M. Shishkin & V. N. Germanova. (2019) Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. Vestnik oftal'mologii 135:6, pages 42.
Crossref
Crossref
S. Lazreg, Z. Merad, M.T. Nouri, R. Garout, A. Derdour, N. Ghroud, R. Kherroubi, M. Meziane, S. Belkacem, O. Ouhadj, C. Baudouin & M. Tiar. (2018) Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. Journal Français d'Ophtalmologie 41:10, pages 945-954.
Crossref
Crossref
Anton Hommer, Doreen Schmidl, Martina Kromus, Ahmed M Bata, Klemens Fondi, René M Werkmeister, Carina Baar, Leopold Schmetterer & Gerhard Garhöfer. (2018) Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. European Journal of Ophthalmology 28:4, pages 385-392.
Crossref
Crossref
Gábor Holló, Andreas Katsanos, Kostas G. Boboridis, Murat Irkec & Anastasios G. P. Konstas. (2017) Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs 78:1, pages 39-64.
Crossref
Crossref